Grace Therapeutics, Inc.
For the period ended Sep 17, 2026. Filed Jul 28, 2026.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Sep 17, 2026 · Filed Jul 28, 2026
Contents
Cover page
Show cover page
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934
Filed by the Registrant ☒
Filed by a Party other than the Registrant ☐
Check the appropriate box:
| ☐ | Preliminary Proxy Statement |
|---|
| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|---|
| ☒ | Definitive Proxy Statement |
|---|
| ☐ | Definitive Additional Materials |
|---|
| ☐ | Soliciting Material Pursuant to §240.14a-12 |
|---|
Grace Therapeutics, Inc.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check all boxes that apply):
| ☒ | No fee required |
|---|
| ☐ | Fee paid previously with preliminary materials |
|---|
| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |
|---|
Grace Therapeutics, Inc.
103 Carnegie Center, Suite 300
Princeton, New Jersey 08540
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
To Be Held on September 17, 2026
To our Stockholders:
You are cordially invited to attend the 2026 Annual Meeting of Stockholders and any adjournments or postponements thereof (the “2026 Annual Meeting” or the “Annual Meeting”) of GRACE THERAPEUTICS, INC., a Delaware corporation (the “Company”). The Annual Meeting will be held virtually on September 17, 2026, at 8:30 a.m. Eastern Time atwww.virtualshareholdermeeting.com/GRCE2026. You will not be able to attend the Annual Meeting in person. The Annual Meeting will be held for the following purposes:
| 1. | To elect the five nominees for director named in the proxy statement accompanying this Notice of Annual Meeting of Stockholders (the “Proxy Statement”) for a one-year term expiring at the 2027 Annual Meeting of Stockholders. |
| 2. | To approve, on an advisory basis, the compensation of our named executive officers. |
| 3. | To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending March 31, 2027. |
| 4. | To approve, on an advisory basis, the frequency of future advisory votes on the compensation of our named executive officers. |
| 5. | To transact such other business as may properly be brought before the Annual Meeting. |
Our Board recommends that stockholders vote: FOR ALL for Proposal No. 1; FOR Proposals No. 2 and No. 3; and 1 YEAR for Proposal No. 4;
These items of business are more fully described in the Proxy Statement.
The Annual Meeting will be held virtually through a live webcast. You will be able to attend the Annual Meeting, submit questions and vote during the live webcast by visitingwww.virtualshareholdermeeting.com/GRCE2026 and entering the 16-digit Control Number included in (i) your Notice of Internet Availability of Proxy Materials (the “Notice”), (ii) your proxy card or voting instruction form in the enclosed proxy materials or (iii) the instructions that you received via email. Please refer to the additional logistical details and recommendations in the Proxy Statement. You may log-in to the Annual Meeting beginning at 8:15 a.m. Eastern Time on September 17, 2026.
The record date for the Annual Meeting is July 20, 2026 (the “Record Date”). Only stockholders of record as of the close of business on the Record Date may vote at the Annual Meeting. We will commence mailing the Notice to our stockholders on or about July 28, 2026, which will contain instructions on how to vote at the Annual Meeting as well as how to access the Proxy Statement and our 2026 Annual Report on Form 10-K.
It is important that your shares be represented at the Annual Meeting regardless of the size of your holdings. Whether or not you plan to attend the Annual Meeting, please provide your proxy by following the instructions described in the Proxy Statement.
By Order of the Board of Directors,
/s/ Prashant Kohli
Prashant Kohli
Chief Executive Officer
Princeton, New Jersey
July 28, 2026
Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Stockholders to Be Held on September 17, 2026 at 8:30 a.m. Eastern Time online atwww.virtualshareholdermeeting.com/GRCE2026.
Copies of our Proxy Materials, consisting of the Notice of Annual Meeting of Stockholders, the Proxy Statement and Accompanying Form of Proxy Card, and our 2026 Annual Report on Form 10-K, are available free of charge atwww.proxyvote.comand our website, www.gracetx.com.
YOUR VOTE IS IMPORTANT
If your shares are held in a brokerage account or with a bank or another nominee record holder, please be sure to mark your voting choices on the voting instruction form provided to you by your broker, bank, or other nominee. If you fail to specify your voting instructions, your shares will not be voted on certain proposals due to rules applicable to broker voting, and we may incur additional costs to solicit votes.
GRACE THERAPEUTICS, INC.
103 Carnegie Center, Suite 300
Princeton, New Jersey 08540
PROXY STATEMENT
FOR THE 2026 ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD AT 8:30 A.M., EASTERN TIME, ON SEPTEMBER 17, 2026
IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE ANNUAL MEETING TO BE HELD ON SEPTEMBER 17, 2026
We are making this Proxy Statement and the accompanying form of proxy card, and our 2026 Annual Report on Form 10-K (the “Annual Report”), available electronically via the internet atww www.virtualshareholdermeeting.com/GRCE2026 and our website, www.gracetx.com. If you wish to receive a paper or email copy of these documents, please follow the instructions contained in the Notice of Internet Availability of Proxy Materials (the “Notice”). There is no charge for requesting a copy.
The Notice will be mailed to our stockholders on or about July 28, 2026, in connection with the solicitation of proxies on behalf of our Board of Directors (our “Board”) for use at our 2026 Annual Meeting of Stockholders, to be held on September 17, 2026 at 8:30 a.m., Eastern Time, virtually atwww.virtualshareholdermeeting.com/GRCE2026, and at any adjournment or postponement thereof (the “2026 Annual Meeting” or the “Annual Meeting”). Whether or not you plan to attend the Annual Meeting, please follow the instructions on the Notice so that your shares may be voted at the Annual Meeting. You may submit your proxy by mail, by telephone, or through the internet by following the instructions set forth on the Notice.
Except as otherwise indicated, references in this Proxy Statement to “Grace,” “Grace Therapeutics,” “the Company,” “we,” “us” and “our” refer to Grace Therapeutics, Inc. (formerly known as Acasti Pharma Inc.) and its consolidated subsidiary.
MEETING AGENDA
| Proposals | Page | Voting Required for Approval | Board Recommendation |
|---|---|---|---|
| Proposal No. 1: To elect the five nominees for director named in this Proxy Statement for a one-year term expiring at the 2027 Annual Meeting of Stockholders (the “2027 Annual Meeting”) | 7 | The five nominees for director receiving a plurality of the votes cast “FOR” election will be elected as directors for a one-year term expiring at the 2027 Annual Meeting | “FOR ALL” for the election of the named director nominees |
| Proposal No. 2: To approve, on an advisory basis, the compensation of our named executive officers | 8 | Affirmative vote of the majority of votes cast on this Proposal | “FOR” the approval, on an advisory basis, of the compensation of our named executive officers |
| Proposal No. 3: To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending March 31, 2027 | 9 | Affirmative vote of the majority of votes cast on this Proposal | “FOR” the ratification of the appointment of KPMG LLP |
| Proposal No. 4: To approve, on an advisory basis, the frequency of future advisory votes on the compensation of our named executive officers. | 10 | Affirmative vote of the majority of votes cast on this Proposal | “1 YEAR” as the frequency of future advisory votes on the compensation of our named executive officers |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.